



Howard Mulligan, Partner
IBM Building
590 Madison Avenue, Suite 1800
New York, NY 10022
Phone: 212.524.5000
Fax: 212.524.5050
Direct Phone: 212.524.5055
Direct Fax:
Email: howard.mulligan@gmlaw.com

August 15, 2022

OTC Markets Group, Inc.
304 Hudson Street, 3rd Floor
New York, NY 10013

RE: Attorney Letter, Adequate Current Information and Disclosure
Filing by 4Cable TV International, Inc. (CATV)
Quarterly Report for the Period Ended June 30, 2022 and related disclosures

Ladies and Gentlemen:

As part of our representation of 4Cable TV International, Inc., a corporation organized and existing under the laws of the state of Florida (“CATV” or the “Issuer”), we have been asked to review the current information supplied by the Issuer to OTC Markets Group, Inc. (“OTC Markets Group”) described in the next paragraph.

The Issuer has requested that we render a sufficiency of adequate information opinion in connection with the filing by the Issuer of its Quarterly Report for the Period ending June 30, 2022, published on August 15, 2022 (the “Report”) pursuant to the OTC Markets Group, Inc. Pink Basic Disclosure Guidelines, Rule 15c2-11(a)(5) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 144(c)(2) of the Securities Act of 1933, as amended (the “Securities Act”). OTC Markets Group is entitled to rely on this letter (“Letter”) in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

We are authorized to practice law in the State of New York and the Federal Courts of the United States. We are also permitted to practice before the U.S. Securities and Exchange Commission (SEC). We are not currently, nor have we in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency. We are not currently, nor have we been in the past five years, suspended or barred from practicing in any state or jurisdiction, and we have not been charged in a civil or criminal case.

We do not currently beneficially own, nor have we in the past beneficially owned, any shares of the Issuer, nor do we have, and in the past have not had, any agreement to receive in the future any shares of the Issuer's securities.

We have reviewed the following documents and related information posted at www.otcmarkets.com and publicly available through the OTC disclosures and News Service in connection with the preparation of this Letter, which is believed to be reliable:

Quarterly Report of Information Pursuant to Rule 15c2-1 1 for the period ending June 30, 2022, which includes:

- a. The Issuer's History
- b. Addressees of Principal Executives
- c. Security Information
- d. Issuance History
- e. Description of the Issuer's Business, Product and Services
- f. Description of the Issuer's Facilities
- g. Company Insiders (Officers, Directors and Control Persons)
- h. Third Party Providers
- i. Issuer's Certification
- j. Financial Statements

We have relied entirely on information obtained from public officials, the chief executive officer and sole member of the board of directors of the Issuer and other sources in the rendering of this Letter and assume that all such sources are reliable. We have examined such corporate records and documents and have asked such questions of law as were considered necessary or appropriate for the purpose of writing this Letter. We have reviewed and relied on information from the Secretary of State of Florida and the Secretary of State of Nevada. We have personally met with and discussed the above documentation with, and have received representations from, Mr. Michael Feldenkrais, the chief executive officer and sole member of Issuer's board of directors. However, we have not conducted an independent investigation of the facts underlying such representations. In the event that the facts and information in all such documents and representations are determined not to be true, this Letter shall be null and void in its entirety.

There has been no information concerning the Issuer and the Securities that are publicly available through the OTC Disclosure and News Service since May 16, 2022, other than information which has been published to www.otcmarkets.com and the Report which is the subject of this Letter. In issuing this Letter, we are of the opinion that the information referred to herein:

(i) Constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act;

(ii) Includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the securities under Rule 15c2-1 1 under the Securities Exchange Act of 1934; and

(iii) Complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, which are located on the internet at www.otcmarkets.com.

We understand that the Report will be submitted by the Issuer for posting through the OTC Disclosure and News Service.

The financial information reflected in the disclosure statement was not audited. The financial information was compiled by Roberto Gonzalez, C.P.A., the acting chief financial officer of CATV, and put into proper order by management.

The Issuer's transfer agent is:

Integral Transfer Agency, Inc.
635 16th St.
Niagara Falls, NY 14301
716-402-8539

We have confirmed that the transfer agent is registered with the SEC via the official SEC website and its EDGAR system at <http://www.sec.gov/edgar/searchedgar/webusers.htm>. We reviewed the information that has been published by the Issuer through the OTC Disclosure and News Service, and with Mr. Feldenkrais to discuss such information. After inquiry of Mr. Feldenkrais, and consultation with the aforementioned transfer agent, we represent that, to the best of our knowledge based on such inquiry, neither the Issuer nor any 5% holder are currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

We have reviewed previous filings and determined the neither the Issuer nor the Issuer's predecessors were a "shell company" as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

Caveat Emptor:

CATV has been given the Caveat Emptor designation since July 14, 2021. Accordingly, the following information is provided:

Mr. Feldenkrais is the Chief Executive Officer, the sole member of the Board of Directors and voting control shareholder of CATV. Mr. Feldenkrais's business address is 23100 SW 192nd Ave., Suite B, Miami, Florida 33170. Mr. Feldenkrais currently owns five (5) Series A Preferred Shares of CATV, which amounts to the control block in CATV in accordance with CATV's organizational documents. Mr. Feldenkrais also currently owns 1,595.60 Series B Preferred Shares, which amounts to 41% of all the Series B Preferred Shares of CATV outstanding and \$1,275,000.00 of Convertible Promissory Notes of CATV. Mr. Feldenkrais, by way of a company owned and controlled by him called Central Health and Innovation, LLC, currently owns 237,922,655 Common Shares of CATV, which amounts to 6.59 % of all Common Shares of CATV outstanding.

Mr. Feldenkrais acquired his interests in CATV as follows:

On December 27, 2020, Mr. Feldenkrais purchased the control block of five (5) Series A Preferred Shares of CATV from Michael Zoyes, former CEO of CATV, in a private transaction.

On December 31, 2020, Mr. Feldenkrais, through Central Health and Innovation, LLC, received 741 Series B Preferred Shares of CATV and \$135,000.00 of Convertible Promissory Notes of CATV in connection with CATV's acquisition of the Healthcare & Wellness LLC and related entities, in consideration for his equity ownership in such entities. On or about January 29, 2022, Central Health and Innovation, LLC had converted both the Series B Preferred Shares and Convertible Promissory Note received in that transaction to 237,922,655 shares of Common Stock of CATV.

On February 9, 2021, Mr. Feldenkrais received 1,596 Series B Preferred Shares of CATV and \$1,275,000.00 in Convertible Promissory Notes of CATV as part of CATV's acquisition of CIGN LLC, as consideration for his equity ownership in CIGN LLC.

Other Insiders of CATV acquired their respective interests in CATV as follows:

KK Family Investments LLC currently owns 382.94 Series B Preferred Shares of CATV, which amounts to approximately 10 % of all Series B Preferred Shares of CATV outstanding, 422,483,626 shares of Common Stock of CATV, which amounts to 11.71% of all Common Stock of CATV outstanding, and Convertible Promissory Notes of CATV in the aggregate amount of \$306,000. On or about January 29, 2022, KK Family Investments LLC had converted 1317 Series B Preferred Shares and an amount of \$560,000.00 in Convertible Promissory Notes to arrive at its current holding of 422,483,626 shares of Common Stock of CATV as a result of the CATV acquisitions of Healthcare and Wellness Clinics of America, LLC and Corporation Clinic, Inc. on December 31, 2020. KK Family Investments LLC also received an additional 382.94 Series B Preferred Shares and \$714,000.00 in Convertible Promissory Notes on February 9, 2021, as part of CATV's acquisition of CIGN LLC, in consideration for its respective equity holding in CIGN LLC. The business address of KK Family Investments LLC is 812 Riverside Drive, Pompano Beach, Florida 33062.

Roberto Gonzalez, acting chief financial officer of CATV, currently owns 957.36 Series B Preferred Shares of CATV, which amounts to 21.6% of all Series B Preferred Shares outstanding and Convertible Promissory Notes of CATV in the aggregate amount of \$765,000. Mr. Gonzalez obtained these Series B Preferred Shares and Convertible Promissory Notes in consideration for CATV's acquisition of CIGN LLC on February 9, 2021 in consideration for his respective equity holding in CIGN LLC. Mr. Gonzalez did not receive any interests in CATV as compensation for his role as acting chief financial officer. His business address is 3211 Ponce De Leon Blvd., Suite 200, Coral Gables, Florida 33134.

Joseph Julian Craan currently owns 255.30 Series B Preferred Shares of CATV, which amounts to 5.77% of all Series B Preferred Shares outstanding and Convertible Promissory Notes of CATV in the aggregate amount of \$204,000. Mr. Craan obtained these Series B Preferred Shares and Convertible Promissory Notes on February 9, 2021, as part of CATV's acquisition of CIGN

LLC, in consideration for his respective equity holding in CIGN LLC. His business address is 3212 W. Hallandale Beach Blvd., Hallandale, Florida 33009.

Sergey Finkelshteyn currently owns 225.26 Series B Preferred Shares of CATV, which amounts to 5.09% of all Series B Preferred Shares outstanding and Convertible Promissory Notes of CATV in the aggregate amount of \$180,000. Mr. Finkelshteyn obtained these Series B Preferred Shares and Convertible Promissory Notes on February 9, 2021, as part of CATV's acquisition of CIGN LLC, in consideration for his respective equity holding in CIGN LLC. His business address is 2999 NE 1921 Street, Suite 904, Miami, Florida 33180.]

No other party owns 5% or more of any class of CATV's outstanding securities.

All of the Preferred Shares of CATV issued to Mr. Feldenkrais, directly or indirectly, both Series A Preferred Shares and Series B Preferred Shares, as well as the Convertible Promissory Notes of CATV issued to Mr. Feldenkrais, contained a legend stating that the securities have not been registered under the Securities Act and setting forth or referring to restrictions on transferability and sale of the securities.

All of the Series B Preferred Shares of CATV issued to KK Family Investments LLC, Mr. Gonzalez, Mr. Craan and Mr. Finkelshteyn as well as the Convertible Promissory Notes of CATV issued to each of them, contained a legend stating that the securities have not been registered under the Securities Act and setting forth or referring to restrictions on transferability and sale of the securities.

The Report subject of this Letter was prepared by Mr. Feldenkrais with assistance from Roberto Gonzalez, C.P.A., the acting chief financial officer of CATV, as well as attorneys from our firm (but not with regard to any calculations). All financial information in the Report had been supplied by CATV and we rely entirely on CATV's representations as to the accuracy of such information. The address of our firm is set forth in the letterhead at the top of this Letter. As stated above, our firm has neither received nor been promised any securities of CATV as compensation for our services. As also stated above, we do not own, either directly or beneficially, any shares of any class of CATV or any debt securities of CATV.

No other party participated in any manner in the preparation of the Report.

We have made specific inquiry of Mr. Feldenkrais and, based upon such inquiries and other information available to us, any sales of CATV's securities by insiders within the twelve month period prior to this Letter have been made in compliance with Rule 144, including, without limitation, any required filings of Form 144, and nothing has come to our attention indicating that any of the insiders is in possession of any material non-public information regarding CATV that would prohibit any of them from buying or selling the securities under Rules 10b-5 or 105-1 under the Exchange Act. In point of fact, no actual sales by insiders occurred during this period.

We have confirmed with management of CATV that management is not aware of any promotional activity concerning CATV's stock within the previous two years. Further, we have confirmed with management of CATV that management is not aware of any investigation of

OTC Markets Group, Inc.

August 15, 2022


Page 6

CATV or of any beneficial owner, officer, director or legal counsel of CATV by any federal or state regulatory authority, including the SEC.

OTC Markets Group is entitled and authorized to rely upon this Letter in determining whether CATV has made adequate information publicly available within the meaning of Rule 144(c)(2) under the Securities Act. No person other than OTC Markets Group, is entitled to rely on this Letter, but full permission is granted to OTC Markets, Group, to publish this Letter through the OTC Disclosure and News Service for viewing by the public and regulators.

This Letter is rendered only as of the date hereof and not as of any subsequent date and this Letter does not include any representation regarding compliance with any state security law or any federal securities law except as specifically provided herein.

Very truly yours,


GREENSPOON MARDER